Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, Telangana, India.
Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, Telangana, India.
Bioorg Med Chem Lett. 2019 Jan 15;29(2):284-290. doi: 10.1016/j.bmcl.2018.11.036. Epub 2018 Nov 17.
A series of novel 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives have been synthesized in good to excellent yields. Through the copper-catalyzed azide-alkyne cycloaddition via reaction of 7-(prop-2-ynyl)-7H-pyrrolo[2,3-d]pyrimidine and aryl, heteroaryl and alkyl azides in the presence of CuSO·5HO and sodium ascorbate. These compounds were evaluated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv strain. Most of these pyrrolopyrimidine-triazole hybrids exhibited good anti tubercular activity. The antimycobacterial assay results showed that the minimum inhibitory concentration of compounds 4q and 4r were 0.78 µg/mL. The molecular docking results also had shown highest Moldock score for same compounds. These novel compounds exhibited good inhibition activities and further structure-activity studies of the derivatives had shown promising features to use in antitubercular therapy.
已经合成了一系列新型 1H-吡咯并[2,3-d]嘧啶-1,2,3-三唑衍生物，产率良好至优秀。通过铜催化的叠氮化物-炔烃环加成反应，在 CuSO·5HO 和抗坏血酸钠存在下，7-(丙-2-炔基)-7H-吡咯并[2,3-d]嘧啶与芳基、杂芳基和烷基叠氮化物反应。这些化合物被评估了对结核分枝杆菌 H37Rv 菌株的体外抗分枝杆菌活性。这些吡咯并嘧啶-三唑杂合体大多数表现出良好的抗结核活性。抗分枝杆菌试验结果表明，化合物 4q 和 4r 的最小抑菌浓度为 0.78 µg/mL。分子对接结果也显示出相同化合物的最高 Moldock 得分。这些新型化合物表现出良好的抑制活性，进一步对衍生物的结构-活性研究显示出在抗结核治疗中具有应用前景。
